Rockwell Medical (RMTI) vs Zhengye Biotechnology (ZYBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rockwell Medical (RMTI) has outperformed Zhengye Biotechnology (ZYBT) over the past year, losing 33.7% versus a loss of 62.7%. Zhengye Biotechnology is the larger company by market cap ($53.2 million vs $32.3 million), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RMTI | ZYBT |
|---|---|---|
| Share price | $8.02 | $1.12 |
| Market cap | $32.32M | $53.16M |
| 1-day change | 0.00% | -2.44% |
| YTD return | -3.37% | -0.01% |
| 1-year return | -33.72% | -62.67% |
| 5-year return | -87.85% | — |
| Forward P/E | 114.57 | — |
| EPS (TTM) | $-1.34 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.90 | $8.01 |
| 52-week low | $4.89 | $0.616 |
| Distance from 52-week high | -37.83% | -86.00% |
| Analyst consensus | none | — |
| Avg. price target upside | +149.38% | — |
| Average volume | 26.44K | 5.10M |
| Shares outstanding | 4.03M | 47.39M |
| Employees | 157 | 269 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RMTI has outperformed ZYBT by 28.9 percentage points over the past year.
About Rockwell Medical
RMTI stock →Rockwell Medical, Inc., together with its subsidiaries, engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. It offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, bicarbonate cartridges, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers.
Health Care · Biotechnology: Pharmaceutical Preparations · 157 employees
About Zhengye Biotechnology
ZYBT stock →Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.
Health Care · Biotechnology: Pharmaceutical Preparations · 269 employees
RMTI vs ZYBT FAQ
Which is bigger, Rockwell Medical or Zhengye Biotechnology?
Zhengye Biotechnology (ZYBT) is larger, with a market capitalization of $53.16M compared with $32.32M for Rockwell Medical (RMTI).
Which stock has performed better over the past year, RMTI or ZYBT?
RMTI returned -33.72% over the past 12 months, compared with -62.67% for ZYBT (price return, excluding dividends). Past performance does not predict future results.
Are Rockwell Medical and Zhengye Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.